Episode

Episode 175 - Joe Jimenez - Co-Founder & Managing Director at Aditum Bio

Podcast
The BioHub - by Avetix
Published
May 19, 2026
Duration seconds
2575
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/max-brennan4/episodes/Episode-175---Joe-Jimenez---Co-Founder--Managing-Director-at-Aditum-Bio-e3jj62c
Audio
https://anchor.fm/s/f0076084/podcast/play/120215052/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-19%2F424454086-44100-2-3e69074a244ad.mp3
JSON
/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-175-joe-jimenez-co-founder-managing-director-at-aditum-bio
Markdown
/podcast/the-biohub-by-avetix-7252289/episode-175-joe-jimenez-co-founder-managing-director-at-aditum-bio.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/the-biohub-by-avetix-7252289/episodes/episode-175-joe-jimenez-co-founder-managing-director-at-aditum-bio/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/the-biohub-by-avetix-7252289/episode-175-joe-jimenez-co-founder-managing-director-at-aditum-bio.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

Today’s guest is Joe Jimenez, one of the most influential leaders in modern biopharma. Joe previously served as CEO of Novartis, where he led the company through a major strategic transformation and helped establish it as one of the world’s leading innovative medicines companies. Today, he is the co-founder and managing director of Aditum Bio, a biotech venture firm focused on building breakthrough therapeutics companies by advancing promising science into the clinic. Aditum Bio are a new model of biotech venture capital uniquely positioned to rapidly translate scientific discoveries into innovative new medicines. Aditum Bio brings together unmatched scientific and domain expertise, combined with operational capabilities that accelerate drug development. They have an agile, collaborative model enables rapid company formation, planning, and execution, empowering teams to explore promising science and bring therapies to patients faster.